Longtime shareholder, former poster here and now frequent lurker.
Had already written AMRN asking about their efforts to educate PBMs and insurance companies, citing current Lovaza NRx market share stats (Lovaza NRx still almost 2/3). This morning, I followed up by pasting/forwarding your post with further questions about what is being done to educate PBMs/insurers to address misunderstandings/lack of information of this type.
Also contacted CVS Caremark (my PBM, Silverscript plan) in writing and within an hour received a callback, in which I inquired about my coverage for Vascepa for 2019 and expressed a desire to communicate with someone about the letter you posted.
The rep said Vascepa is Tier 4 and my cost for 90 day supply (4g/day) would be $309.71 if done via mail order, $411.99 if filled at local CVS pharmacy. I expressed concern about Tier 4 designation, and asked that such concern be forwarded.
I also asked that my concern about CVS' apparent, mistaken belief that there is a "lower-cost, clinically equivalent alternative drug" and CVS' not covering Vascepa in some of its plans be forwarded so that I can discuss same and provide information to appropriate persons at CVS.
Rep said my concerns are being forwarded and I would be contacted further.
Noticed that some board members are considering a DTC campaign and other members' concerns with same (with which concerns I generally agree). Might that energy be better spent communicating instead with the right people at insurance companies and PBMs, providing them with links to NEJM article, Vascepa hcp webpage, pleiotropic effects article zumantu recently posted, Mason presentation, etc., and pointing out that they would be reducing their costs and increasing their profits (and saving their patients' lives and suffering) by moving Vascepa immediately to Tier 2? I don't expect such a change, but at least would hope they might be more receptive when approached by Amarin.
What would happen if informed insureds began communicating, in numbers, with their PBMs/insurers, alerting them to recently reported science that, when acted upon by physicians and PBMs, will save lives and reduce their costs? Some companies might be receptive to listening to their customers (to be sure, their decision-makers have heard of NEJM and AHA).
Market Data 
Markets 
AI
